DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge
- 1 September 2007
- Vol. 366 (1) , 73-83
- https://doi.org/10.1016/j.virol.2007.04.010
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primateVirology, 2007
- Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell FunctionJournal of Virology, 2006
- Signature for Long-Term Vaccine-Mediated Control of a Simian and Human Immunodeficiency Virus 89.6P Challenge: Stable Low-Breadth and Low-Frequency T-Cell Response Capable of Coproducing Gamma Interferon and Interleukin-2Journal of Virology, 2005
- Development and Use of a Vaccinia Virus Neutralization Assay Based on Flow Cytometric Detection of Green Fluorescent ProteinJournal of Virology, 2003
- Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA VaccinesJournal of Virology, 2002
- In Search of a Kinder, Gentler VaccineScience, 2002
- Clinical Responses to Undiluted and Diluted Smallpox VaccineNew England Journal of Medicine, 2002
- Transmission potential of smallpox in contemporary populationsNature, 2001
- Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal modelVaccine, 1996
- Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) DiseaseNew England Journal of Medicine, 1987